Gonasi Set

Gonasi Set is a prescription injectable solution that contains the hormone human chorionic gonadotropin (hCG). It is supplied as a sterile liquid for intramuscular or subcutaneous administration and is marketed in the European Union for use in fertility and reproductive endocrinology. The product is classified as a gonadotropin hormone and is intended for professional medical use under a physician’s supervision.

Gonasi Set is employed in several reproductive medicine protocols to support ovulation and luteal function. It is commonly used in assisted reproductive technologies and specific pediatric endocrine conditions.

- Induction of ovulation in women undergoing intra‑uterine insemination or timed intercourse. - Luteal phase support following in vitro fertilisation (IVF) embryo transfer. - Treatment of infertility caused by anovulation or luteal insufficiency. - Management of cryptorchidism in male infants to stimulate testicular descent. - Adjunct therapy in controlled ovarian hyperstimulation cycles.

Side effects of Gonasi Set vary in frequency and severity. Most patients experience mild, transient reactions, while rare serious events may require medical attention.

Common: - Injection site pain, redness, or swelling. - Headache or mild dizziness. - Nausea or abdominal discomfort. - Temporary flu‑like symptoms such as low‑grade fever.

Serious: - Ovarian hyperstimulation syndrome (OHSS) presenting with rapid weight gain, abdominal distension, or shortness of breath. - Allergic reactions including rash, itching, swelling, or anaphylaxis.

Before prescribing Gonasi Set, clinicians should evaluate patient history and monitor for potential risks. The following precautions are recommended:

- Verify absence of pregnancy in women receiving hCG for ovulation induction. - Assess for ovarian cysts or prior episodes of OHSS. - Use caution in patients with thyroid disorders, as hCG can affect thyroid hormone levels. - Monitor blood pressure in individuals with cardiovascular disease. - Adjust dose or discontinue if signs of severe OHSS develop. - Counsel patients on proper injection technique to reduce local reactions.

Gonasi Set may interact with other medications or hormonal agents, influencing efficacy or safety. Consider the following when co‑administering:

Avoid: - Concurrent use of high‑dose estrogen preparations that may exacerbate OHSS. - Uncontrolled thyroid hormone therapy that could be destabilized by hCG.

Use with caution: - Gonadotropin‑releasing hormone (GnRH) agonists or antagonists used in IVF protocols. - Anticoagulants, as hCG can increase thrombotic risk in susceptible patients. - Steroids that may mask early signs of allergic reactions. - Diuretics, which could affect fluid balance during OHSS.